The 2016 World Health Organization classification of tumours of the central nervous system

被引:75
作者
Villa, Chiara [1 ,2 ,3 ]
Miquel, Catherine [4 ]
Mosses, Dominic [5 ]
Bernier, Michele [1 ]
Di Stefano, Anna Luisa [6 ,7 ]
机构
[1] Foch Hosp, Dept Pathol Cytol & Anat, 40 Rue Worth, F-92151 Suresnes, France
[2] Paris Descartes Univ, Cochin Inst, INSERM, U1016,CNRS,UMR 8104, 24 Rue Faubourg St Jacques, F-75014 Paris, France
[3] Univ Liege, CHU Liege, Dept Endocrinol, Sart Tilman B35, B-4000 Liege, Belgium
[4] St Louis Hosp, Dept Pathol Anat, F-75010 Paris, France
[5] Univ Manchester, Div Neurosci & Expt Psychol, Fac Biol Med & Hlth, Manchester M13 9PL, Lancs, England
[6] Foch Hosp, Dept Neurol, F-75013 Suresnes, France
[7] UPMC Univ Paris 06, Sorbonne Univ, Brain & Spine Inst, INSERM,U1127,CNRS,UMR 7225, F-92151 Paris, France
来源
PRESSE MEDICALE | 2018年 / 47卷 / 11-12期
关键词
TERT PROMOTER MUTATIONS; ADJUVANT TEMOZOLOMIDE; ASTROCYTIC TUMORS; ELDERLY-PATIENTS; DIFFUSE GLIOMAS; FREQUENT ATRX; PHASE-III; IDH; GLIOBLASTOMA; BRAIN;
D O I
10.1016/j.lpm.2018.04.015
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The 2016 WHO classification of tumours of the central nervous system represents the new paradigm among the specialists in the brain tumours and proposes a new approach combining histopathological and molecular features into diagnosis named 'integrated diagnosis'. The aim of this challenge is to overstep the interobserver variability of diagnosis based on previous classifications in order to ensure homogenous biological entities with a more accurate clinical significance. Over the last two decades, several molecular aberrations into gliomagenesis were highlighted and then confirmed as emerging biomarkers through prognostic stratification. In particular, IDH1/IDH2 genes mutations, 1p/19q codeletion and mutations in genes encoding histone H3 variants drastically changed the knowledge about diffuse gliomas inducing the WHO working group to consider the phenotype-genotype approach. In the present review, the historical development of the diagnosis of brain tumours from the 3D spatial configuration to the integration of multidisciplinary data up to recent molecular alterations is discussed. At the national level, the RENOCLIP network (supported by the National Cancer Institute) contributes to improve the standardization of histological diagnosis and the facilitation of access to molecular biology platforms for the detection of genetic aberrations necessary for integrated diagnosis. Importantly, the French POLA cohort allowed to test the clinical impact of the new criteria introduced by 2016 WHO classification of CNS tumours confirming the high accuracy in predicting clinical behaviour for diffuse gliomas.
引用
收藏
页码:E187 / E200
页数:14
相关论文
共 67 条
[1]   Glioblastoma: pathology, molecular mechanisms and markers [J].
Aldape, Kenneth ;
Zadeh, Gelareh ;
Mansouri, Sheila ;
Reifenberger, Guido ;
von Deimling, Andreas .
ACTA NEUROPATHOLOGICA, 2015, 129 (06) :829-848
[2]   Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma [J].
Buckner, Jan C. ;
Shaw, Edward G. ;
Pugh, Stephanie L. ;
Chakravarti, Arnab ;
Gilbert, Mark R. ;
Barger, Geoffrey R. ;
Coons, Stephen ;
Ricci, Peter ;
Bullard, Dennis ;
Brown, Paul D. ;
Stelzer, Keith ;
Brachman, David ;
Suh, John H. ;
Schultz, Christopher J. ;
Bahary, Jean-Paul ;
Fisher, Barbara J. ;
Kim, Harold ;
Murtha, Albert D. ;
Bell, Erica H. ;
Won, Minhee ;
Mehta, Minesh P. ;
Curran, Walter J., Jr. .
NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (14) :1344-1355
[3]   Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402 [J].
Cairncross, Gregory ;
Wang, Meihua ;
Shaw, Edward ;
Jenkins, Robert ;
Brachman, David ;
Buckner, Jan ;
Fink, Karen ;
Souhami, Luis ;
Laperriere, Normand ;
Curran, Walter ;
Mehta, Minesh .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (03) :337-343
[4]   Benefit From Procarbazine, Lomustine, and Vincristine in Oligodendroglial Tumors Is Associated With Mutation of IDH [J].
Cairncross, J. Gregory ;
Wang, Meihua ;
Jenkins, Robert B. ;
Shaw, Edward G. ;
Giannini, Caterina ;
Brachman, David G. ;
Buckner, Jan C. ;
Fink, Karen L. ;
Souhami, Luis ;
Laperriere, Normand J. ;
Huse, Jason T. ;
Mehta, Minesh P. ;
Curran, Walter J., Jr. .
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (08) :783-+
[5]   Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes [J].
Castel, David ;
Philippe, Cathy ;
Calmon, Raphael ;
Le Dret, Ludivine ;
Truffaux, Nathalene ;
Boddaert, Nathalie ;
Pages, Melanie ;
Taylor, Kathryn R. ;
Saulnier, Patrick ;
Lacroix, Ludovic ;
Mackay, Alan ;
Jones, Chris ;
Sainte-Rose, Christian ;
Blauwblomme, Thomas ;
Andreiuolo, Felipe ;
Puget, Stephanie ;
Grill, Jacques ;
Varlet, Pascale ;
Debily, Marie-Anne .
ACTA NEUROPATHOLOGICA, 2015, 130 (06) :815-827
[6]   IDH mutations in glioma and acute myeloid leukemia [J].
Dang, Lenny ;
Jin, Shengfang ;
Su, Shinsan M. .
TRENDS IN MOLECULAR MEDICINE, 2010, 16 (09) :387-397
[7]   Cancer-associated IDH1 mutations produce 2-hydroxyglutarate [J].
Dang, Lenny ;
White, David W. ;
Gross, Stefan ;
Bennett, Bryson D. ;
Bittinger, Mark A. ;
Driggers, Edward M. ;
Fantin, Valeria R. ;
Jang, Hyun Gyung ;
Jin, Shengfang ;
Keenan, Marie C. ;
Marks, Kevin M. ;
Prins, Robert M. ;
Ward, Patrick S. ;
Yen, Katharine E. ;
Liau, Linda M. ;
Rabinowitz, Joshua D. ;
Cantley, Lewis C. ;
Thompson, Craig B. ;
Heiden, Matthew G. Vander ;
Su, Shinsan M. .
NATURE, 2009, 462 (7274) :739-U52
[8]  
DAUMASDUPORT C, 1987, J NEURO-ONCOL, V4, P317
[9]  
DAUMASDUPORT C, 1988, CANCER-AM CANCER SOC, V62, P2152, DOI 10.1002/1097-0142(19881115)62:10<2152::AID-CNCR2820621015>3.0.CO
[10]  
2-T